Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nacresertib in healthy adult subjects
NCT07566130Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of nacresertib (8 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Cmax and 8 more. Started Apr 2025; status: completed.
02
Drugs
nacresertib
Beyond the preview
Go deeper on NCT07566130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566130.